ArticleBritish journal of cancer2018
Impact of NICE guidance on tamoxifen prescribing in England 2011-2017: an interrupted time series analysis.
Article in British journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04058418 (Impact of Familial Cancer Specialist Recommendation on Chemoprevention Prescribing for Familial Breast Cancer), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Familial Cancer Specialist Recommendation on Chemoprevention Prescribing for Familial Breast Cancer (FBC) Risk in Primary Care: Short Survey and Interrupted Time Series Analysis
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population-Based Cross-Sectional Study of Uptake of NICE Guidance.Diabetes, obesity & metabolism · 2026Observational
- The breast cancer risk assessment pathway in England: a systems analysis of current challenges and ways to improve.British journal of cancer · 2026Article
- RxTrends: An R-based Shiny Application for Visualising Open Data on Prescribed Medications in Ireland.HRB open research · 2025Article
- Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women diagnosed with invasive breast cancer in England.British journal of cancer · 2023Article
- Improving primary care identification of familial breast cancer risk using proactive invitation and decision support.Familial cancer · 2021Article
- Specialist recommendation for chemoprevention medications in patients at familial risk of breast cancer: a cross-sectional survey in England.Journal of community genetics · 2021Article
- Personalized early detection and prevention of breast cancer: ENVISION consensus statement.Nature reviews. Clinical oncology · 2020Review
- Suboptimal prescribing behaviour associated with clinical software design features: a retrospective cohort study in English NHS primary care.The British journal of general practice : the journal of the Royal College of General Practitioners · 2020Article
- Variation in responsiveness to warranted behaviour change among NHS clinicians: novel implementation of change detection methods in longitudinal prescribing data.BMJ (Clinical research ed.) · 2019Article
- Article
- Beliefs About Medication and Uptake of Preventive Therapy in Women at Increased Risk of Breast Cancer: Results From a Multicenter Prospective Study.Clinical breast cancer · 2019Article
- Six months on: NHS England needs to focus on dissemination, implementation and audit of its low-priority initiative.Journal of the Royal Society of Medicine · 2019Article
- Making It Happen: Middle Managers' Roles in Innovation Implementation in Health Care.Worldviews on evidence-based nursing · 2018Article
- Prescribing Variation in General Practices in England Following a Direct Healthcare Professional Communication on Mirabegron.Journal of clinical medicine · 2018Article
- Comment on 'Impact of NICE guidance on tamoxifen prescribing in England 2011-2017: an interrupted time series analysis'.British journal of cancer · 2018Article
- Reply to Comment on 'Impact of NICE guidance on tamoxifen prescribing in England 2011-2017: an interrupted time series analysis".British journal of cancer · 2018Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTamoxifen was recommended by NICE in 2013 for chemoprevention of breast cancer, but a recent survey suggested only a quarter of GPs are aware of this. We set out to measure the uptake of tamoxifen, and the alternative raloxifene, in national prescribing data sets.
methodsTamoxifen and raloxifene data were extracted from England's monthly prescribing data sets, October 2010-October 2017. We used interrupted time series analysis to reveal national and local responses to guidelines. We investigated variation between practices by calculating percentiles for prescribing rates and ratios of change.
resultsWe found an increase in monthly tamoxifen prescribing following release of the guidelines, with an increase in gradient (p = 0.001) but no step change (p = 0.342). Alongside a small change in raloxifene prescribing we estimate 8450 women took up chemoprevention between 2013 and 2016. We did not find evidence that this was limited to a small group of practices.
conclusionsOur results suggest that the uptake of new guidance on chemoprevention has been slow and has potentially left women exposed to avoidable risk. Improving dissemination of guidance to healthcare professionals and routinely monitoring implementation could help reduce this risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.